Engineered nanoparticles for the detection, treatment and prevention of atherosclerosis: how close are we?

Luong T.H. Nguyen, Aristo Muktabar, Jinkai Tang, Vinayak P. Dravid, C. Shad Thaxton, Subbu Venkatraman, Kee Woei Ng*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

Atherosclerosis is one of the leading causes of morbidity and mortality worldwide. Nanotechnology has provided the possibility of designing nanoparticles that can translocate through tissues and home in to atherosclerotic plaques to achieve desired diagnostic, therapeutic, theranostic or ‘theralivery’ outcomes. Although nanomedicine approaches have demonstrated exciting possibilities, clinical reality is still distant and challenges are aplenty, such as specificity of targeting and nanotoxicity. Nevertheless, developments in formulations, delivery strategies and experimental models over the coming years will generate new knowledge to define the true potential of this field. This review discusses the most recent developments, current challenges and future possibilities.

Original languageEnglish (US)
Pages (from-to)1438-1446
Number of pages9
JournalDrug Discovery Today
Volume22
Issue number9
DOIs
StatePublished - Sep 2017

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Engineered nanoparticles for the detection, treatment and prevention of atherosclerosis: how close are we?'. Together they form a unique fingerprint.

Cite this